which blocks apoptosis, resulted in partial protection against the drug. We conclude that Pgp upregulation is not likely to be a significant contributor to Imatinib resistance.
Introduction
Imatinib, also known as STI571 or Gleevec ® (Novartis), is a potent inhibitor of the BCR/ABL and c-KIT protein tyrosine kinases 1, 2, 3 and is being used for the treatment of chronic myelogenous leukemia (CML), Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and gastrointestinal stromal tumors (GIST).
Imatinib was found to be highly efficacious in phase II trials 4, 5 and has recently been approved by the Food and Drug Administration Board (FDA) for the treatment of Ph+ chronic phase CML and Kit positive GIST. The development of resistance to Imatinib in some patients, especially those with CML in blast crisis or ALL, is a major limitation for therapy. In patients resistance has been correlated in a few cases with bcr/abl gene amplification and, in many cases, with the presence of point mutations leading to amino acid substitutions within the kinase domain of BCR/ABL 6, 7, 8, 9, 10, 11 .
Furthermore, some of the BCR/ABL mutants identified in patients were able to confer varying degrees of resistance to the growth inhibitory effects of Imatinib when expressed in cell lines 11 . However, not all leukemic samples from resistant patients displayed overexpression or mutation of BCR/ABL, therefore alternative or additional mechanisms of drug resistance to Imatinib remain to be determined.
Cell lines selected for Imatinib resistance in vitro have been obtained by exposure to increasing doses of Imatinib over a period of 3 -6 months [12] [13] [14] . Analysis of these cell lines has shown that, in contrast to data from patients, resistance was often associated with upregulation of BCR/ABL but, where examined, point mutations in the kinase domain were not found. [16] [17] [18] . In order to determine if Pgp upregulation could confer resistance to Imatinib, Pgp was overexpressed in K562 cells, which were derived from a patient with CML and depend on BCR/ABL activity for survival and growth. The Imatinib sensitivity of K562 cells overexpressing Pgp was compared to parental K562 cells and to K562 cells overexpressing the anti-apoptotic factor Bcl-x L . Imatinib has been shown to induce apoptosis in BCR/ABL positive cells by suppressing expression of the anti-apototic factor Bcl-x L that is induced by the oncogene in a Stat-5 dependent manner 19, 20 .
Materials and Methods

Construction of expression plasmids
The 4.1kb mdr1.1 cDNA (Genbank accession number M14758) coding for Pgp was obtained from ATCC as an EcoR1 fragment within the pGEM3Zf(-) vector. An XbaI fragment containing the mdr1.1 cDNA was excised and blunt-ended using DNAPolI Klenow fragment (Pharmacia, Buckinghamshire, Eng) as per the manufacturer's instructions. The fragment was cloned into the HpaI site of the pRUFneo retroviral expression vector 21 and checked for correct orientation.
The bcl-x L cDNA was isolated from a cDNA library constructed from leukaemic cell lines. The cDNA was amplified by high-fidelity PCR using Elongase (Stratagene, La Jolla, CA) as per the manufacturer's instructions and cloned into the pRUFneo vector. The cDNA was sequenced to confirm the product cloned was identical to the bcl-x L cDNA (Genbank accession number Z23115).
The pRUFneo(mdr1.1) and pRUFneo(bcl-x L ) constructs were expanded in DH10 E.coli and the plasmids purified using a midi-prep kit (Qiagen, GmbH, Hilden, Germany). 
Analysis of drug efflux
The K562(Pgp+) cells were analyzed in a drug efflux assay as described . 2x10 5 cells/ml were exposed to 0-40µg/ml Daunorubicin for 1-3 days in the presence and absence of Verapamil (10µg/ml) and the absorbance at 490nm
was analysed for triplicate samples. Similarly, 2x10 5 cells/ml were exposed to 0-5µM
Imatinib for 3 days prior to absorbance analysis. The HEL cell line was included as control line that expressed a high level of functional Pgp 23,24 but was not influenced by Imatinib.
Analysis of the apoptotic effects of Imatinib
The same cell lines analyzed in the MTS assay above, were also analyzed for the level of apoptosis observed following treatment with Imatinib as described A. Expression of cell surface Pgp by HEL erythroleukemia cells, parental K562 cells and sorted K562 infectants was measured by indirect immunofluorescence and flow cytometry using Mab U1C2. Neg refers to a control where an irrelevant isotype-matched Mab was used in place of U1C2.
B.
Daunorubicin retention in the presence or absence of 3µM Verapamil was assayed by flow cytometry as described in Materials and Methods. The rate of drug efflux is calculated as the slope of the line derived from the retention of Daunorubicin over the assay period expressed as a percentage of that of inhibitor-treated cells for each time point (as described previously 24 ). The relative rate of efflux was calculated to be 0.152 for K562(none), 0.4222 for K562(Pgp+) and 0.117 for K562(Bcl-xl). A. Whole cell lysates were resolved by electrophoresis and probed by western blotting with detection by chemi-fluorescence for p210 BCR/ABL using antibody to c-Abl, and for tyrosine phosphorylated p210 using anti-phosphotyrosine Mabs.
B. Bands were quantitated using the Typhoon and analyzed with Image-Quant software. The ratios of tyrosine phosphorylated and total p210 for each treatment were calculated after correction for background. Data are expressed relative to the value for each cell line in the absence of drug.
Discussion
Imatinib has been very successful as a specific anti-cancer drug therapy in the treatment of Ph+ leukemias and GIST. 
